You are here
In this session, the speakers discuss the uses and clinical trials of Radium 223 therapy . They discuss the key issues in imaging in advanced prostate cancer. They also discuss patient selection (low- versus. high-volume disease, oligo- vs. polymetastatic disease, aggressive disease detection), treatment benefit (radiographic progression-free survival, lack of bone metastases response on imaging criteria, emerging prostate-specific membrane antigen [PSMA]-targeting molecules as treatment under development). They mention that whole-body magnetic resonance imaging (MRI) - diffusion-weighted imaging (DWI) has potential as ‘one-stop shop’ instead of MRI prostate + CT + bone scan. On comparison of PSMA with whole body markers, Dr. Tunariu mentions that PSMA gives detection while whole body markers give information about response to therapy. They discuss that bone scan has limitations such as being more sensitive to progression than response, assessment of hydroxyapatite deposition but not to cancer, qualitative rather than quantitative, subject to flare-ups. The Prostate Cancer Working Group (PCWG) criteria focus not on imaging but on biomarker development and presence of absence of two new lesions.
- In this session, the host introduced the expert speakers, Prof. Eleni Efstathiou, who is an associate professor, Genitourinary Medical Oncology...